PPA
ANTH

Parametric Portfolio Associates’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Parametric Portfolio Associates’s Portfolio ANTH Stock Details ANTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,364
Closed -$7K – 3847
2016
Q4 		$7K Buy
1,364
+60
+5% +$1.04K ﹤0.01% 3767
2016
Q3 		$33K Buy
+1,304
New +$32.9K ﹤0.01% 3742

Other funds holding ANTH

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Parametric Portfolio Associates's ANTH Position: Q1 2017 in Review

Parametric Portfolio Associates sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q1 2017, closing a stake of 1,364 shares — an estimated $7K sold.

Parametric Portfolio Associates first reported a position in ANTH in Q3 2016 and held it in 2 quarters. The position peaked at $33K in Q3 2016. 60 funds tracked by Wall St. Rank hold ANTH as of Q1 2017.

  • Parametric Portfolio Associates reported no remaining Anthera Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Parametric Portfolio Associates sold 1,364 Anthera Pharmaceuticals, Inc. shares in Q1 2017, an estimated $7K.
  • Parametric Portfolio Associates first reported a position in Anthera Pharmaceuticals, Inc. in Q3 2016 and held it in 2 quarters.
  • Parametric Portfolio Associates's Anthera Pharmaceuticals, Inc. position peaked at $33K in Q3 2016.
  • 60 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q1 2017.

Based on Parametric Portfolio Associates's 13F filing for Q1 2017, filed 8 May 2017.